Anticancer agent delivery system using pH-sensitive metal nanoparticles
09757474 · 2017-09-12
Assignee
Inventors
Cpc classification
A61K9/0019
HUMAN NECESSITIES
B82Y5/00
PERFORMING OPERATIONS; TRANSPORTING
Y10S977/906
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10S977/773
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
A61N5/062
HUMAN NECESSITIES
Y10T428/2982
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
A61K41/0052
HUMAN NECESSITIES
A61K9/5094
HUMAN NECESSITIES
A61K31/122
HUMAN NECESSITIES
A61K47/6923
HUMAN NECESSITIES
International classification
A61K9/14
HUMAN NECESSITIES
A61K41/00
HUMAN NECESSITIES
A61K31/122
HUMAN NECESSITIES
A61K9/50
HUMAN NECESSITIES
A61K9/16
HUMAN NECESSITIES
Abstract
The present invention relates to a method for effectively delivering an anticancer drug into cancer cells by binding the anticancer drug to pH-sensitive metal nanoparticles so as to be separated from cancer cells. The pH-sensitive metal nanoparticles according to the present invention may be heated by photothermal therapy, thereby effectively killing cancer cells in conjunction with the isolated anticancer drug.
Claims
1. pH-sensitive metal nanoparticles for therapy of cancer, being loaded with an anticancer drug through a linkage bond, wherein the anticancer drug is released from the metal nanoparticles in an acidic pH condition to kill a cancel cell, and the metal nanoparticles form aggregations in an acidic pH condition for photothermal therapy so as to kill the cancer cell by absorbing red or near-infrared light, and wherein the anticancer drug is released from the pH-sensitive nanoparticles by cleaving a different bond than the linkage bond.
2. The pH-sensitive metal nanoparticles of claim 1, having a compound anchored onto a surface thereof, said compound being represented by the following Chemical Formula 1: ##STR00006##
3. The pH-sensitive metal nanoparticles of claim 1, ranging in size from about 5 nm to 15 nm.
4. The pH-sensitive metal nanoparticles of claim 1, wherein the anticancer drug is released by hydrolysis.
5. The pH-sensitive metal nanoparticles of claim 1, wherein the anticancer drug is selected from the group consisting of doxorubicin, Methotrexate, Paclitaxel, Cisplatin, Bleomycin, and a combination thereof.
6. The pH-sensitive metal nanoparticles of claim 2, wherein the anticancer drug has a —NH.sub.2 group, said —NH.sub.2 group being substituted by a compound represented by the following Chemical Formula 2, when releasing: ##STR00007##
7. A metal nanoparticle being conjugated with a compound represented by the following Chemical Formula 3: ##STR00008##
8. A compound represented by the following Chemical Formula 4: ##STR00009##
9. A pH-sensitive metal nanoparticle having a compound anchored onto a surface thereof, said compound represented by the following Chemical Formula 1, being conjugated with a dye having a primary amine group or an —OH group: ##STR00010##
10. The pH-sensitive metal nanoparticle of claim 9, wherein the dye is Alexa Fluor 488 hydrazide.
11. A pH-sensitive metal nanoparticle, being conjugated with an agent having a primary amine group or a —OH group, said agent being selected from the group consisting of an anticancer agent, a light sensitizer, a gene therapeutic, a protein therapeutic, and a combination thereof.
12. An anticancer agent having one or more —NH.sub.2 groups, wherein at least one —NH.sub.2 group is substituted by a compound represented by the following Chemical Formula 2: ##STR00011##
13. The pH-sensitive metal nanoparticles of claim 1, wherein the anticancer agent is covalently linked by a reaction between a —COOH group of the linkage compound and an —NH2 group of the anticancer agent, and released from the metal nanoparticles by cleaving a different bond from the linkage bond.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
MODE FOR INVENTION
Examples
(8) Synthesis of pH-Sensitive Ligand
(9) A solution of lipoic acid in anhydrous chloroform was mixed at room temperature for 5 min with 1.3 equivalents of carbonyl diimidazole under a vacuum condition with stirring, followed by separating the reaction solution layer from the remaining carbonyl diimidazole. Ethylene diamine was dissolved in an amount corresponding to 5 equivalents of the lipoic acid in anhydrous chloroform in a nitrogen atmosphere, cooled in an ice bath, and mixed for 1 hour with the separated reaction solution by stirring. The resulting reaction solution containing the product was extracted three times with 10% NaCl and once with deionized water and mixed at room temperature for 24 hours with citraconic anhydride to form a solid substance. After filtration, the solid substance was dissolved in an aqueous solution which was adjusted to a pH of 9 with NaOH. The resulting solution was stirred at room temperature for 4 hours together with one equivalent of NaBH.sub.4 to afford a pH-sensitive ligand.
(10) Synthesis of Gold Nanoparticles Stabilized with Citrate
(11) A solution of the gold precursor HAuCl.sub.4 in distilled water was heated at 120° C. for 30 min with stirring, and then for an additional 2 h, together with trisodium citrate, with stirring. In this course, the trisodium citrate acted as a reducing agent and a surface ligand, with the solution turning from yellow to red, indicating the construction of gold nanoparticles. Thereafter, the solution was cooled at room temperature with stirring. (Ind. Chem. Res. 2007, 46, 3128-3136)
(12) Synthesis of pH-Sensitive Gold Nanoparticles
(13) The citrate-stabilized gold nanoparticles were added to an aqueous solution containing an excess of the synthetic pH-sensitive ligand and mixed at room temperature for 8 hours by stirring. Because the dithiol of the pH-sensitive ligand binds more strongly to the surface of the gold nanoparticles than does the carboxylic acid of citrate, the pH-sensitive ligand is exchanged for the citrate. Excess ligands were removed by dialysis.
(14) Conjugation of pH-Sensitive Gold Nanoparticle with Drug
(15) 1) Synthesis of pH-Sensitive Gold Nanoparticle-Alexa Fluor 488 Hydrazide Conjugate
(16) A dispersion of pH-sensitive gold nanoparticles in a phosphate buffer, pH 7.0, was stirred, together with excess 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and sulfo-N-hydroxy succinimide (sulfo-NHS), at room temperature for 10 min to activate the pH-sensitive gold nanoparticles. The solution was dialyzed three times against a phosphate buffer, pH 7, to remove excess EDC and sulfo-NHS. The dialyzed solution was mixed at room temperature for 3 hours with a dispersion of Alexa Fluor 488 hydrazide in distilled water with stirring, so as to form a pH-sensitive gold nanoparticle-Alexa Fluor 488 hydrazide conjugate. Excess Alexa Fluor 488 hydrazide was removed by three rounds of dialysis with distilled water.
(17) In the context of the conjugation, EDC and sulfo-NHS, both for use in the conjugation, acted as molecules to promote the formation of an amide bond between the terminal carboxylic acid of the pH-sensitive gold nanoparticles and the primary amine group of Alexa Fluor 488 hydrazide, as illustrated in
(18) Upon exposure of the conjugate to a weak acidic condition such as an environment presented by endosomes within cells, the surface molecules on the pH-sensitive gold nanoparticles undergo hydrolysis so that the Alexa Fluoro 488 hydrazide is released from the gold nanoparticles, as illustrated in
(19) 2) Synthesis of pH-Sensitive Gold Nanoparticle-Doxorubicin Conjugate
(20) Excess 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and sulfo-N-hydroxy succinimide (sulfo-NHS) were added to a dispersion of pH-sensitive gold nanoparticles in a phosphate buffer, pH 7.0, and stirred at room temperature for 10 min to activate the pH-sensitive gold nanoparticles. The solution was dialyzed three times against a phosphate buffer, pH 7, to remove excess EDC and sulfo-NHS. The dialyzed solution was mixed at room temperature for 3 hours with a dispersion of doxorubicin in a phosphate buffer, pH 8.0, with stirring, so as to form a pH-sensitive gold nanoparticle-doxorubicin conjugate.
(21) The pH-sensitive gold nanoparticle-doxorubicin conjugate was used, without further purification, for culturing cells. In the context of the conjugation, EDC and sulfo-NHS, both for use in the conjugation, acted as molecules to promote the formation of an amide bond between the terminal carboxylic acid of the pH-sensitive gold nanoparticles and the primary amine group of doxorubicin, as illustrated in
(22) When the pH-sensitive gold nanoparticles encounter endosomes presenting a weak acidic environment, the surface molecules on the pH-sensitive gold nanoparticles are hydrolyzed to release the doxorubicin from the gold nanoparticles.
(23) Concurrently, the surface charge of the pH-sensitive gold nanoparticles changes from (−) to (+) so that the particles aggregate due to electrostatic attraction. As the pH-sensitive gold nanoparticles aggregate, their light absorption band shifts toward longer wavelengths. Therefore, the pH-sensitive gold nanoparticles of the present invention allow for photothermal therapy with long wavelength light as well as for chemotherapy through the delivery of an anticancer drug to cancer cells.
(24) Fluorescence Assay
(25) KCN was added to a solution of pH-sensitive gold nanoparticle-Alexa Fluor 488 hydrazide conjugate to dissolve the gold. This gold-dissolved solution and a solution of pH-sensitive gold nanoparticle-Alexa Fluor 488 hydrazide conjugate were examined for light absorption and fluorescence properties.
(26) As can be seen in the absorbance spectra of
(27) Upon the treatment of the gold nanoparticles with KCN, the characteristic absorbance of gold nanoparticles disappeared, indicating that the gold nanoparticles were completely dissolved (left panel, red).
(28) Turning to fluorescence spectra (
(29) The fluorescence spectra describe the extinguishment of dye fluorescence by gold nanoparticles, demonstrating that the pH-sensitive gold nanoparticles were successfully loaded with dye to form a stable conjugate.
(30) When the conjugate in which a molecule of interest is introduced into the terminal of the surface molecules anchored onto the surface of the pH-sensitive gold nanoparticle is exposed to a weak acidic condition, the terminal functional group is cleaved by hydrolysis to release the molecule of interest, with the concomitant formation of aggregates of nearby particles by electrostatic attraction.
(31) To confirm this, the pH-sensitive gold nanoparticle-Alexa Fluor 488 hydrazide conjugates were dispersed at pH 7.6 and pH 1.0, and absorbance and fluorescence spectra were measured.
(32) As shown in the absorbance spectra of
(33) As can be seen in the fluorescence spectra of
(34) Taken together, the data obtained above demonstrate that the pH-sensitive nanoparticle-Alexa Fluor 488 hydrazide conjugates release the Alexa Fluor 488 hydrazide moiety in an acidic condition while the gold nanoparticles aggregate with the absorbance band shifting toward longer wavelengths.
(35)
(36) Once the conjugates are internalized into cells, the conjugates undergo hydrolysis, when encountering an intracellular acidic pH environment such as endosomes, to induce the dissociation of the Alexa Fluor 488 hydrazide moiety. Thereupon, the fluorescence of Alexa Fluor 488 hydrazide which has been extinguished by energy transfer into the gold nanoparticles revives, so that green fluorescence is visualized within cells under a fluorescence microscope.
(37) Fluorescence was observed at a very small intensity in the cells 10 to 30 min after incubation with the conjugate, but started to intensify from one hour after the incubation and reached the maximum three hours after the incubation.
(38) This result shows that after the internalization of the pH-sensitive gold nanoparticles into cells, Alexa Fluor 488 hydrazide is released gradually.
(39) Taking advantage of the phenomenon that after internalization into cells, the pH-sensitive gold nanoparticle conjugates undergo hydrolysis to gradually dissociate the conjugated molecule with time, the pH-sensitive gold nanoparticles of the present invention can be used as a drug delivery system.
(40) Drug Test
(41) In this Example, the anticancer drug doxorubicin was employed. Doxorubicin works to induce cell death by intercalating DNA. It emits yellow-reddish fluorescence at near 600 nm. When the conjugates penetrate into cancer cells, doxorubicin is dissociated from the gold nanoparticles by hydrolysis under an acidic condition and translocates into the nucleus which thus emits yellow-reddish fluorescence. Test results are shown in
(42) Breast cancer cells in test groups were incubated with the pH-sensitive gold nanoparticle-doxorubicin conjugates to induce the internalization of the conjugate (middle panel,
(43) For comparison, cells were incubated with doxorubicin-free pH-sensitive gold nanoparticles (left panel,
(44) The intranuclear delivery of doxorubicin can be qualitatively analyzed in terms of nuclear yellow-reddish fluorescence as measured by fluorescence microscopy.
(45) Because of the absence of doxorubicin, the cells treated with the pH-sensitive gold nanoparticles alone did not show fluorescence in the nucleus 24 hours after incubation.
(46) In contrast, the fluorescence of doxorubicin started to appear with time in the cells treated with the pH-sensitive gold nanoparticle-doxorubicin conjugates. The nuclei were observed to be clearly fluorescent 12 hours after incubation (4.sup.th column, middle panel,
(47) On the other hand, the cells incubated with doxorubicin alone started to exhibit fluorescence after only one hour of incubation (1.sup.st column, right panel,
(48) While intense fluorescence is detected within a short culture time upon treatment with doxorubicin alone, the fluorescence intensity of pH-sensitive gold nanoparticle-doxorubicin conjugates is relatively slowly increased.
(49) However, similar fluorescence intensities were obtained after 24 hours in both cell groups, indicating that levels of doxorubicin delivered into the nucleus become similar after a sufficient period of time. That is, most of the doxorubicin conjugated to the pH-sensitive gold nanoparticles is released.
(50) In order for doxorubicin to be visualized in the cells incubated with the pH-sensitive gold nanoparticle-doxorubicin conjugates, the conjugates must be internalized into the cells and hydrolyzed to dissociate the doxorubicin therefrom.
(51) Hence, a series of processes of internalizing the pH-sensitive metal nanoparticle-doxorubicin conjugates into cells and hydrolyzing the conjugates at acidic endosomes to release doxorubicin is conducted relatively slowly so that it takes relatively much time for doxorubicin to accumulate in the nucleus of cells.
(52) Based on the data, the pH-sensitive metal nanoparticles on which a surface molecule is conjugated with an anticancer drug can be used as an anticancer drug delivery system which allows drug release to be easily controlled, compared to the drug alone.
(53) When administered into the body, anticancer drugs alone can accumulate in the nuclei of cells within a short period of time, thus exerting pharmaceutical effects like the administration of an excessive amount of drug. In contrast, conjugates with the pH-sensitive metal nanoparticles release the drug for a relatively long period of time, showing pharmaceutical effects like sustained-release type of drugs.
(54) In this way, if drug release is controlled through the conjugate system of the pH-sensitive metal nanoparticles, not only can the adverse effects related to overdose or insufficient dose of drug be reduced, but also the inconvenience of patients attributed to frequent administration can be alleviated. In addition, the pH-sensitive gold nanoparticles enjoy the advantage of improving the poor solubility of anticancer drugs thanks to their high solubility and recruiting a variety of anticancer drugs.
(55) Gene therapeutics such as siRNA as well as conventional anticancer agents such as doxorubicin can be used in the present invention.
(56) In addition to the delivery of anticancer drugs, the pH-sensitive metal nanoparticles function to perform potent photothermal therapy as they aggregate after releasing the anticancer drugs for chemotherapy. Therefore, the pH-sensitive metal nanoparticles are advantageous in that they can more effectively kill cancer cells through a combination of chemotherapy and photothermal therapy.
(57) With these advantages, the pH-sensitive metal nanoparticle-anticancer drug conjugate is expected to be an effective anticancer drug delivery system.